Immunology
Roche and Novartis’ Xolair set for FDA priority review in food allergies
Genentech (Roche) and Novartis’ Xolair (omalizumab) could soon become a treatment option for multiple food allergy reactions after the FDA…
Ionis and Otsuka sign agreement for hereditary angioedema therapy
Ionis Pharmaceuticals has signed a licence agreement under which Otsuka Pharmaceutical will gain sole rights to market the ligand-conjugated antisense…
CymaBay seeks FDA approval for primary biliary cholangitis therapy
CymaBay Therapeutics has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) seeking approval for…
AstraZeneca agrees to acquire Icosavax for $1.1bn
AstraZeneca has signed a definitive agreement to initiate a tender offer for the acquisition of US-based clinical-stage biopharmaceutical company Icosavax…
Seismic Therapeutic secures $121m to develop immunology pipeline
Seismic Therapeutic has secured $121m in a Series B funding round to advance the development of its immunology pipeline. New…
FDA fast tracks Alladapt’s multi-food allergy immunotherapy
The US Food and Drug Administration (FDA) has granted a fast track designation to Alladapt Immunotherapeutics’ IgE-mediated multi-food oral immunotherapy…
Certa plans pivotal scleroderma trial after Phase II data readout
Australian biotech Certa Therapeutics aims to start a pivotal trial with FT011 in late 2024, following the positive Phase II…
Leading innovators in antibody encoding polynucleotide libraries for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,…
Leading innovators in anti-RSV vaccines for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,…
Leading innovators in cell immunomodulation for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,…
